An increase in CLU expression, as well as other RevSC markers including Anxa1 and Basp1, is also evident following chemotherapy treatment in genetically engineered mouse organoid models of CRC [106], and this correlates with what is observed in CRC PDOs [24]. This evidence concerns the gene BASP1 and colorectal carcinoma.